FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281566794> ?p ?o ?g. }

• W4281566794 endingPage "e2213945" @default.
• W4281566794 startingPage "e2213945" @default.
• W4281566794 abstract "New-onset atrial fibrillation (AF) is commonly reported in patients with severe infections. However, the absolute risk of thromboembolic events without anticoagulation remains unknown.To investigate the thromboembolic risks associated with AF in patients with pneumonia, assess the risk of recurrent AF, and examine the association of initiation of anticoagulation therapy with new-onset AF.This population-based cohort study used linked Danish nationwide registries. Participants included patients hospitalized with incident community-acquired pneumonia in Denmark from 1998 to 2018. Statistical analysis was performed from August 15, 2021, to March 12, 2022.New-onset AF.Thromboembolic events, recurrent AF, and all-cause death. Estimated risks were calculated for thromboembolism without anticoagulation therapy, new hospital or outpatient clinic contact with AF, initiation of anticoagulation therapy, and all-cause death at 1 and 3 years of follow-up. Death was treated as a competing risk, and inverse probability of censoring weights was used to account for patient censoring if they initiated anticoagulation therapy conditioned on AF.Among 274 196 patients hospitalized for community-acquired pneumonia, 6553 patients (mean age [SD], 79.1 [11.0] years; 3405 women [52.0%]) developed new-onset AF. The 1-year risk of thromboembolism was 0.8% (95% CI, 0.8%-0.8%) in patients without AF vs 2.1% (95% CI, 1.8%-2.5%) in patients with new-onset AF without anticoagulation; this risk was 1.4% (95% CI, 1.0%-2.0%) among patients with AF with intermediate stroke risk and 2.8% (95% CI, 2.3%-3.4%) in patients with AF with high stroke risk. Three-year risks were 3.5% (95% CI, 2.8%-4.3%) among patients with intermediate stroke risk and 5.3% (95% CI, 4.4%-6.5%) among patients with high stroke risk. Among patients with new-onset AF, 32.9% (95% CI, 31.8%-34.1%) had a new hospital contact with AF, and 14.0% (95% CI, 13.2%-14.9%) initiated anticoagulation therapy during the 3 years after incident AF diagnosis. At 3 years, the all-cause mortality rate was 25.7% (95% CI, 25.6%-25.9%) in patients with pneumonia without AF vs 49.8% (95% CI, 48.6%-51.1%) in patients with new-onset AF.This cohort study found that new-onset AF after community-acquired pneumonia was associated with an increased risk of thromboembolism, which may warrant anticoagulation therapy. Approximately one-third of patients had a new hospital or outpatient clinic contact for AF during the 3-year follow-up, suggesting that AF triggered by acute infections is not a transient, self-terminating condition that reverses with resolution of the infection." @default.
• W4281566794 created "2022-05-27" @default.
• W4281566794 creator A5006360424 @default.
• W4281566794 creator A5038405190 @default.
• W4281566794 creator A5063647251 @default.
• W4281566794 creator A5072757201 @default.
• W4281566794 creator A5076675313 @default.
• W4281566794 creator A5076999140 @default.
• W4281566794 creator A5078667862 @default.
• W4281566794 date "2022-05-26" @default.
• W4281566794 modified "2023-10-05" @default.
• W4281566794 title "Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy" @default.
• W4281566794 cites W1769504474 @default.
• W4281566794 cites W1973617793 @default.
• W4281566794 cites W1978670003 @default.
• W4281566794 cites W1999468381 @default.
• W4281566794 cites W2002320845 @default.
• W4281566794 cites W2012030177 @default.
• W4281566794 cites W2012952526 @default.
• W4281566794 cites W2018316412 @default.
• W4281566794 cites W2040452288 @default.
• W4281566794 cites W2053207109 @default.
• W4281566794 cites W2096246254 @default.
• W4281566794 cites W2097854437 @default.
• W4281566794 cites W2109626958 @default.
• W4281566794 cites W2115109558 @default.
• W4281566794 cites W2126607056 @default.
• W4281566794 cites W2127985968 @default.
• W4281566794 cites W2136489990 @default.
• W4281566794 cites W2162508946 @default.
• W4281566794 cites W2219591537 @default.
• W4281566794 cites W2314364287 @default.
• W4281566794 cites W2465032265 @default.
• W4281566794 cites W2540928320 @default.
• W4281566794 cites W2541013163 @default.
• W4281566794 cites W2546446487 @default.
• W4281566794 cites W2551469077 @default.
• W4281566794 cites W2598476089 @default.
• W4281566794 cites W2605788004 @default.
• W4281566794 cites W2738888953 @default.
• W4281566794 cites W2802841177 @default.
• W4281566794 cites W2810227481 @default.
• W4281566794 cites W2858897535 @default.
• W4281566794 cites W2890279337 @default.
• W4281566794 cites W2912139642 @default.
• W4281566794 cites W2968936545 @default.
• W4281566794 cites W2974260392 @default.
• W4281566794 cites W2996658149 @default.
• W4281566794 cites W3082188176 @default.
• W4281566794 cites W3097416314 @default.
• W4281566794 cites W3134526193 @default.
• W4281566794 cites W3176468033 @default.
• W4281566794 cites W4254637496 @default.
• W4281566794 cites W4296004092 @default.
• W4281566794 doi "https://doi.org/10.1001/jamanetworkopen.2022.13945" @default.
• W4281566794 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35616941" @default.
• W4281566794 hasPublicationYear "2022" @default.
• W4281566794 type Work @default.
• W4281566794 citedByCount "7" @default.
• W4281566794 countsByYear W42815667942022 @default.
• W4281566794 countsByYear W42815667942023 @default.
• W4281566794 crossrefType "journal-article" @default.
• W4281566794 hasAuthorship W4281566794A5006360424 @default.
• W4281566794 hasAuthorship W4281566794A5038405190 @default.
• W4281566794 hasAuthorship W4281566794A5063647251 @default.
• W4281566794 hasAuthorship W4281566794A5072757201 @default.
• W4281566794 hasAuthorship W4281566794A5076675313 @default.
• W4281566794 hasAuthorship W4281566794A5076999140 @default.
• W4281566794 hasAuthorship W4281566794A5078667862 @default.
• W4281566794 hasBestOaLocation W42815667941 @default.
• W4281566794 hasConcept C126322002 @default.
• W4281566794 hasConcept C127413603 @default.
• W4281566794 hasConcept C137668524 @default.
• W4281566794 hasConcept C142724271 @default.
• W4281566794 hasConcept C187212893 @default.
• W4281566794 hasConcept C201903717 @default.
• W4281566794 hasConcept C2776102371 @default.
• W4281566794 hasConcept C2777914695 @default.
• W4281566794 hasConcept C2779161974 @default.
• W4281566794 hasConcept C2780645631 @default.
• W4281566794 hasConcept C2908647359 @default.
• W4281566794 hasConcept C71924100 @default.
• W4281566794 hasConcept C72563966 @default.
• W4281566794 hasConcept C78519656 @default.
• W4281566794 hasConcept C99454951 @default.
• W4281566794 hasConceptScore W4281566794C126322002 @default.
• W4281566794 hasConceptScore W4281566794C127413603 @default.
• W4281566794 hasConceptScore W4281566794C137668524 @default.
• W4281566794 hasConceptScore W4281566794C142724271 @default.
• W4281566794 hasConceptScore W4281566794C187212893 @default.
• W4281566794 hasConceptScore W4281566794C201903717 @default.
• W4281566794 hasConceptScore W4281566794C2776102371 @default.
• W4281566794 hasConceptScore W4281566794C2777914695 @default.
• W4281566794 hasConceptScore W4281566794C2779161974 @default.
• W4281566794 hasConceptScore W4281566794C2780645631 @default.
• W4281566794 hasConceptScore W4281566794C2908647359 @default.
• W4281566794 hasConceptScore W4281566794C71924100 @default.
• W4281566794 hasConceptScore W4281566794C72563966 @default.

• next